An observational study in Campylobacter Infections, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Hospices Civils de Lyon · Observational
Among 23 studies in Primary Immunodeficiency Diseases with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Primary Immunodeficiency Diseases · France.
Among the 23 studies in Primary Immunodeficiency Diseases with a site in France, this one is the 11th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 2024, is one of 14 observational ones, and was the 22nd registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
This study's planned enrollment of 30 is below the median of 137 across 77 observational studies indexed under Primary Immunodeficiency Diseases.
Browse Primary Immunodeficiency Diseases studies →4 of the 23 studies in Primary Immunodeficiency Diseases with a site in France are open now.
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: Up to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2024.
Median enrollment 40 across the 9 interventional studies, 95 across the 14 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Hospices Civils de Lyon has 1 study filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Primary Immunodeficiency Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04459689Imagine InstituteCOVID-19 in PID Survey | 2027-02-18 |
Among the 23 studies in Primary Immunodeficiency Diseases with a site in France, from their registry updates:
Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples.
As of today, only around 20 cases have been described in the international literature for the last 30 years. The cases are likely highly underreported.
No study describes those recurrent Campylobacter bacteraemias at the scale of a country.
The aim of this multicentre, nationwide, retrospective study is to describe their precise epidemiology in France for the last 25 years, the immune profile of the patients, the specificities of the bacteria involved, the treatments received and the evolution of these infections.
The perspective is to propose a standardization of the medical care of those patients mainly by describing the effective treatments and the explorations of the immune system which should be considered.
French hospitals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Opposition of the patient
Patients presenting at least two distinct episodes of Campylobacter bacteraemia separated by minimum 60 days and an immunodeficiency (innate or acquired) and followed by a French hospital
Other: Characteristics of patients and Campylobacter bacteraemia episodes
Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-demographic characteristics
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count, polyvalent Ig replacement therapy
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-chronic inflammatory bowel disease \[IBD\]
Time frame: Baseline
Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia
-characteristics of bacteraemia: clinical presentation, bacteria (species, antimicrobial susceptibility), secondary localizations, evolution, treatment modalities (antibiotics and immunother
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for May 2025, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →